A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in \<50% of tumor cells.
Epistemonikos ID: 28ea7cc8bc3748dc98d51477c246fee2ad6a3c82
First added on: May 21, 2024